Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 5/20 | 0.56 |
| ▸ | CNR1 | P21554 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | LPAR1 | Q92633 | 6/20 | 0.45 |
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.45 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.45 |
| ▸ | LPAR6 | P43657 | 2/20 | 0.45 |
| ▸ | LPAR4 | Q99677 | 2/20 | 0.45 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19669679 | 1.00 | CNR2 (0.56) | CNR2CNR1ALDH1A1DNM1LMNA | |
| SCHEMBL8952647 | 1.00 | CNR2 (0.56) | CNR2CNR1ALDH1A1DNM1LMNA | |
| SCHEMBL6556754 | 1.00 | CNR2 (0.56) | CNR2CNR1ALDH1A1DNM1LMNA | |
| SCHEMBL9328381 | 1.00 | CNR2 (0.56) | CNR2CNR1ALDH1A1DNM1LMNA | |
| SCHEMBL7800390 | 1.00 | CNR2 (0.56) | CNR2CNR1ALDH1A1DNM1LMNA | |
| SCHEMBL3391670 | 1.00 | CNR2 (0.56) | CNR2CNR1ALDH1A1DNM1LMNA | |
| SCHEMBL11300731 | 1.00 | CNR2 (0.56) | CNR2CNR1ALDH1A1DNM1LMNA | |
| SCHEMBL10520454 | 1.00 | CNR2 (0.56) | CNR2CNR1ALDH1A1DNM1LMNA | |
| SCHEMBL9329951 | 1.00 | CNR2 (0.56) | CNR2CNR1ALDH1A1DNM1LMNA | |
| SCHEMBL31588466 | 1.00 | CNR2 (0.56) | CNR2CNR1ALDH1A1DNM1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080071084-A1 | Using an alcohol in presence of copper catalyst and ligand | ARCHIMICA GMBH (DE) | 2008-03-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080071084-A1 | Using an alcohol in presence of copper catalyst and ligand | NR1H3, NR1H2, ADH1A | CNR2 298/4885CNR1 106/4885ALDH1A1 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.